Filing Details
- Accession Number:
- 0001415889-24-009253
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-27 18:57:28
- Reporting Period:
- 2024-03-25
- Accepted Time:
- 2024-03-27 18:57:28
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1808158 | Repare Therapeutics Inc. | RPTX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1815366 | Michael Zinda | C/O Repare Therapeutics Inc. St-Laurent A8 H4S 1Z9 | Evp, Chief Scientific Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Shares | Disposition | 2024-03-25 | 450 | $4.78 | 73,668 | No | 4 | S | Direct | |
Common Shares | Disposition | 2024-03-26 | 450 | $4.61 | 73,218 | No | 4 | S | Direct | |
Common Shares | Disposition | 2024-03-27 | 450 | $4.62 | 72,768 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Footnotes
- This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the holder on December 22, 2023. On January 30, 2023, the holder was granted 24,550 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on February 1, 2023, of which 8,183 of these RSUs vested on January 30, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.72 to $4.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4).
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.53 to $4.76 inclusive.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.52 to $4.72 inclusive.